tbuckley/cabot-search huggingface dataset:
A Miniaturized, Battery‐Free, Wireless Wound Monitor That Predicts Wound Closure Rate Early
Authors: Nate T. Garland, Joseph W. Song, Tengfei Ma, Yong Jae Kim, Abraham Vázquez‐Guardado, Ayemeh Bagheri Hashkavayi, Sankalp Koduvayur Ganeshan, Nivesh Sharma, Hanjun Ryu, Min‐Kyu Lee, Brandon Sumpio, Margaret A. Jakus, Viviane Forsberg, Rajaram Kaveti, Samuel K. Sia, Aristidis Veves, John A. Rogers, Guillermo A. Ameer, Amay J. Bandodkar
Journal: Advanced Healthcare Materials (2023)

Diabetic foot ulcers are chronic wounds that affect millions and increase the risk of amputation and mortality, highlighting the critical need for their early detection. Recent demonstrations of wearable sensors enable real-time wound assessment, but they rely on bulky electronics, making them difficult to interface with wounds. Herein, a miniaturized, wireless, battery-free wound monitor that measures lactate in real-time and seamlessly integrates with bandages for conformal attachment to the wound bed is introduced. Lactate is selected due to its multifaceted role in initiating healing. Studies in healthy and diabetic mice reveal distinct lactate profiles for normal and impaired healing wounds. A mathematical model based on the sensor data predicts wound closure rate within the first 3 days post-injury with ≈76% accuracy, which increases to ≈83% when pH is included. These studies underscore the significance of monitoring biomarkers during the inflammation phase, which can offer several benefits, including short-term use of wound monitors and their easy removal, resulting in lower risks of injury and infection at the wound site. Improvements in prediction accuracy can be achieved by designing mathematical models that build on multiple wound parameters such as pro-inflammatory and metabolic markers. Achieving this goal will require designing multi-analyte wound monitors.
Alcoholic Setdb1 suppression promotes hepatosteatosis in mice by strengthening Plin2
Authors: Yi Zhang, Yanhui Li, Yang Liu, Hongzhi Wang, Yingli Chen, Bing Zhang, Meiqi Song, Lei Song, Qinchao Ding, Jiannan Qiu, Mingjian Fan, Lihui Qu, Zhigang Wang
Journal: Metabolism (2023)
Overall, plant-based, or animal-based low carbohydrate diets and all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of prospective cohort studies
Authors: Zeinab Ghorbani, Asma Kazemi, Nargeskhatoon Shoaibinobarian, Kate Taylor, Morvarid Noormohammadi
Journal: Ageing Research Reviews (2023)
Distinct Genomic Landscape of Lung Adenocarcinoma from Household Use of Smoky Coal
Authors: Tongwu Zhang, Phuc H. Hoang, Jason Y. Y. Wong, Kaiyun Yang, Kexin Chen, Maria Pik Wong, Roel C. H. Vermeulen, Yunchao Huang, Stephen J. Chanock, Nathaniel Rothman, Qing Lan, Maria Teresa Landi, Wei Hu, Ying Chen, Jihua Li, Yongchun Zhou, George S. Downward, Hongji Dai, Lützen Portengen, Jianxin Shi, Jun Xu
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Distinct Genomic Landscape of Lung Adenocarcinoma from Household Use of Smoky Coal." American Journal of Respiratory and Critical Care Medicine, 208(6), pp. 733–736
Early Detection and Bundled Treatment for Postpartum Hemorrhage
Authors: Adeline A. Boatin, Joseph Ngonzi
Journal: New England Journal of Medicine (2023)

Postpartum hemorrhage is the leading cause of maternal death in developing regions, accounting for 20% of maternal deaths, most of which are preventable.1 This opportunity for prevention is evident by the decrease over time in the contribution of postpartum hemorrhage to maternal death in developed regions, where it accounts for 8% of maternal deaths.1 Bleeding after childbirth is normal and part of the physiologic transition that occurs in the postdelivery period. However, the transition to abnormal bleeding can be swift. Postpartum hemorrhage, which is traditionally defined as blood loss of more than 500 ml, can develop within minutes and can . . .
Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing
Authors: Nicolas Delaleu, Hans-Peter Marti, Philipp Strauss, Miroslav Sekulic, Tarig Osman, Camilla Tøndel, Rannveig Skrunes, Sabine Leh, Einar Svarstad, Albina Nowak, Ariana Gaspert, Elena Rusu, Ivo Kwee, Andrea Rinaldi, Arnar Flatberg, Oystein Eikrem
Journal: Kidney International (2023)

Fabry disease is a rare disorder caused by variations in the alpha-galactosidase gene. To a degree, Fabry disease is manageable via enzyme replacement therapy (ERT). By understanding the molecular basis of Fabry nephropathy (FN) and ERT's long-term impact, here we aimed to provide a framework for selection of potential disease biomarkers and drug targets. We obtained biopsies from eight control individuals and two independent FN cohorts comprising 16 individuals taken prior to and after up to ten years of ERT, and performed RNAseq analysis. Combining pathway-centered analyses with network-science allowed computation of transcriptional landscapes from four nephron compartments and their integration with existing proteome and drug-target interactome data. Comparing these transcriptional landscapes revealed high inter-cohort heterogeneity. Kidney compartment transcriptional landscapes comprehensively reflected differences in FN cohort characteristics. With exception of a few aspects, in particular arteries, early ERT in patients with classical Fabry could lastingly revert FN gene expression patterns to closely match that of control individuals. Pathways nonetheless consistently altered in both FN cohorts pre-ERT were mostly in glomeruli and arteries and related to the same biological themes. While keratinization-related processes in glomeruli were sensitive to ERT, a majority of alterations, such as transporter activity and responses to stimuli, remained dysregulated or reemerged despite ERT. Inferring an ERT-resistant genetic module of expressed genes identified 69 drugs for potential repurposing matching the proteins encoded by 12 genes. Thus, we identified and cross-validated ERT-resistant gene product modules that, when leveraged with external data, allowed estimating their suitability as biomarkers to potentially track disease course or treatment efficacy and potential targets for adjunct pharmaceutical treatment.
Under the umbrella of depression and Alzheimer’s disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy?
Authors: Carla Fonseca, Miren Ettcheto, Joana Bicker, Maria José Fernandes, Amílcar Falcão, Antoni Camins, Ana Fortuna
Journal: Ageing Research Reviews (2023)

Depression and Alzheimer´s disease (AD) are two disorders highly prevalent worldwide. Depression affects more than 300 million people worldwide while AD affects 60% to 80% of the 55 million cases of dementia. Both diseases are affected by aging with high prevalence in elderly and share not only the main brain affected areas but also several physiopathological mechanisms. Depression disease is already ascribed as a risk factor to the development of AD. Despite the wide diversity of pharmacological treatments currently available in clinical practice for depression management, they remain associated to a slow recovery process and to treatment-resistant depression. On the other hand, AD treatment is essentially based in symptomatology relieve. Thus, the need for new multi-target treatments arises. Herein, we discuss the current state-of-art regarding the contribution of the endocannabinoid system (ECS) in synaptic transmission processes, synapses plasticity and neurogenesis and consequently the use of exogenous cannabinoids in the treatment of depression and on delaying the progression of AD. Besides the well-known imbalance of neurotransmitter levels, including serotonin, noradrenaline, dopamine and glutamate, recent scientific evidence highlights aberrant spine density, neuroinflammation, dysregulation of neurotrophic factor levels and formation of amyloid beta (Aβ) peptides, as the main physiopathological mechanisms compromised in depression and AD. The contribution of the ECS in these mechanisms is herein specified as well as the pleiotropic effects of phytocannabinoids. At the end, it became evident that Cannabinol, Cannabidiol, Cannabigerol, Cannabidivarin and Cannabichromene may act in novel therapeutic targets, presenting high potential in the pharmacotherapy of both diseases.
Clinical Examination of the Cranial Nerves
Authors: Rohin Singh, Jordan R. Pollock, M. Lane Moore, Yeonsoo S. Lee, Miles Hudson, Bernard R. Bendok, Naresh P. Patel
Journal: New England Journal of Medicine (2023)

Each cranial nerve has a specific function; the location of cranial-nerve injury can be pinpointed with patient history and careful examination. This video shows how to perform a comprehensive cranial-nerve examination.
A Single-Cell Atlas of Small Airway Disease in Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study
Authors: Steven Booth, Aileen Hsieh, Leila Mostaco-Guidolin, Hyun-Kyoung Koo, Keith Wu, Fatemeh Aminazadeh, Chen Xi Yang, Daniela Quail, Yuhong Wei, Joel D. Cooper, Peter D. Paré, James C. Hogg, Dragoş M. Vasilescu, Tillie-Louise Hackett
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Rationale: Emerging data demonstrate that the smallest conducting airways, terminal bronchioles, are the early site of tissue destruction in chronic obstructive pulmonary disease (COPD) and are reduced by as much as 41% by the time someone is diagnosed with mild (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 1) COPD. Objectives: To develop a single-cell atlas that describes the structural, cellular, and extracellular matrix alterations underlying terminal bronchiole loss in COPD. Methods: This cross-sectional study of 262 lung samples derived from 34 ex-smokers with normal lung function (n = 10) or GOLD stage 1 (n = 10), stage 2 (n = 8), or stage 4 (n = 6) COPD was performed to assess the morphology, extracellular matrix, single-cell atlas, and genes associated with terminal bronchiole reduction using stereology, micro-computed tomography, nonlinear optical microscopy, imaging mass spectrometry, and transcriptomics. Measurements and Main Results: The lumen area of terminal bronchioles progressively narrows with COPD severity as a result of the loss of elastin fibers within alveolar attachments, which was observed before microscopic emphysematous tissue destruction in GOLD stage 1 and 2 COPD. The single-cell atlas of terminal bronchioles in COPD demonstrated M1-like macrophages and neutrophils located within alveolar attachments and associated with the pathobiology of elastin fiber loss, whereas adaptive immune cells (naive, CD4, and CD8 T cells, and B cells) are associated with terminal bronchiole wall remodeling. Terminal bronchiole pathology was associated with the upregulation of genes involved in innate and adaptive immune responses, the interferon response, and the degranulation of neutrophils. Conclusions: This comprehensive single-cell atlas highlights terminal bronchiole alveolar attachments as the initial site of tissue destruction in centrilobular emphysema and an attractive target for disease modification.
Has genetic disposition implications for treatment decisions in atrial fibrillation?
Authors: Felix Bourier, Heribert Schunkert
Journal: Cardiovascular Research (2023)

Genetic disposition largely facilitates the occurrence of atrial fibrillation (AF), stroke, or coronary artery disease.Particularly, genome-wide association studies (GWAS) identified hundreds of genetic variants that modulate the risk of these conditions. 1,2,3Two straightforward questions arise from these observations: first, do the same genetic variants predict reoccurrence of an event in individuals who have had a disease manifestation before, and second, do genetics interact with treatment responses?For coronary artery disease, the answer to both questions is yes.Individuals with a high polygenic risk score (PRS) not only have an about twofold increase for having a myocardial infarction, they have-within the group of coronary artery disease patients-also an about 30% increased risk for a second event. 3At the same time, intensive treatment with statins or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offers the largest treatment benefit for those who have a high polygenic risk. 3
Incremental Utility of First-Pass Perfusion CMR for Prognostic Risk Stratification of Cancer-Associated Cardiac Masses
Authors: Angel T. Chan, Tania Ruiz Maya, Christine Park, Katherine Tak, Nicole Liberman, Raina H. Jain, Michael J. Park, Robert Y. Park, John Grizzard, Gene Kim, William D. Tap, Jose Jessurun, Jennifer Liu, Jiwon Kim, Richard M. Steingart, Jonathan W. Weinsaft
Journal: JACC. Cardiovascular imaging (2023)
A Bumpy Road to Diagnosis
Authors: Jacob J. Cedarbaum, Deepak A. Rao, Hiroto Hatabu, Katherine H. Walker, Joseph Loscalzo
Journal: New England Journal of Medicine (2023)

A 32-year-old woman presented with worsening epigastric pain. She also reported chills, night sweats, a nonproductive cough, intermittent dyspnea and wheezing, and an unintentional 20-lb weight loss.
Palliative clinical trials in advanced chronic liver disease: Challenges and opportunities
Authors: Sumita Verma, Jay Hingwala, Joseph T.S. Low, Arpan A. Patel, Manisha Verma, Stephen Bremner, Yazan Haddadin, Myrick C. Shinall, Paul Komenda, Nneka N. Ufere
Journal: Journal of Hepatology (2023)

Patients with advanced chronic liver disease have a complex symptom burden and many are not candidates for curative options. Despite this, provision of palliative interventions remains woefully inadequate; lack of an evidence base being a contributory factor. Designing and conducting palliative interventional trials in advanced chronic liver disease remain challenging for a multitude of reasons. In this manuscript we review past and ongoing palliative interventional trials. We identify barriers and facilitators and offer guidance on addressing these challenges. We hope that this will reduce the inequity in palliative care provision in advanced chronic liver disease.
Quantifying differences in iron deficiency-attributable anemia during pregnancy and postpartum
Authors: Eliza M. Davidson, Michelle J.L. Scoullar, Elizabeth Peach, Christopher J. Morgan, Pele Melepia, D. Herbert Opi, Hadlee Supsup, Priscah Hezeri, Wilson Philip, Dukduk Kabiu, Kerryanne Tokmun, Rose Suruka, Ruth Fidelis, Arthur Elijah, Peter M. Siba, William Pomat, Benishar Kombut, Leanne J. Robinson, Brendan S. Crabb, Elissa Kennedy, Philippe Boeuf, Julie A. Simpson, James G. Beeson, Freya J.I. Fowkes
Journal: Cell Reports Medicine (2023)

Pregnant women in resource-limited settings are highly susceptible to anemia and iron deficiency, but the etiology of postpartum anemia remains poorly defined. To inform the optimal timing for anemia interventions, changes in iron deficiency-attributable anemia through pregnancy and postpartum need to be understood. In 699 pregnant Papua New Guinean women attending their first antenatal care appointment and following up at birth and 6 and 12 months postpartum, we undertake logistic mixed-effects modeling to determine the effect of iron deficiency on anemia and population attributable fractions, calculated from odds ratios, to quantify the contribution of iron deficiency to anemia. Anemia is highly prevalent during pregnancy and 12 months postpartum, with iron deficiency increasing the odds of anemia during pregnancy and, to a lesser extent, postpartum. Iron deficiency accounts for ≥72% of anemia during pregnancy and 20%–37% postpartum. Early iron supplementation during and between pregnancies could break the cycle of chronic anemia in women of reproductive age.
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
Authors: Cerise Tang, Amy X. Xie, Eric Minwei Liu, Fengshen Kuo, Minsoo Kim, Renzo G. DiNatale, Mahdi Golkaram, Ying-Bei Chen, Sounak Gupta, Robert J. Motzer, Paul Russo, Jonathan Coleman, Maria I. Carlo, Martin H. Voss, Ritesh R. Kotecha, Chung-Han Lee, Wesley Tansey, Nikolaus Schultz, A. Ari Hakimi, Ed Reznik
Journal: Cell Metabolism (2023)

Tumor cell phenotypes and anti-tumor immune responses are shaped by local metabolite availability, but intratumoral metabolite heterogeneity (IMH) and its phenotypic consequences remain poorly understood. To study IMH, we profiled tumor/normal regions from clear cell renal cell carcinoma (ccRCC) patients. A common pattern of IMH transcended all patients, characterized by correlated fluctuations in the abundance of metabolites and processes associated with ferroptosis. Analysis of intratumoral metabolite-RNA covariation revealed that the immune composition of the microenvironment, especially the abundance of myeloid cells, drove intratumoral metabolite variation. Motivated by the strength of RNA-metabolite covariation and the clinical significance of RNA biomarkers in ccRCC, we inferred metabolomic profiles from the RNA sequencing data of ccRCC patients enrolled in 7 clinical trials, and we ultimately identifyied metabolite biomarkers associated with response to anti-angiogenic agents. Local metabolic phenotypes, therefore, emerge in tandem with the immune microenvironment, influence ongoing tumor evolution, and are associated with therapeutic sensitivity.
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level
Authors: Silvia Sirotti, Lene Terslev, Emilio Filippucci, Annamaria Iagnocco, Ingrid Moller, Esperanza Naredo, Florentin A Vreju, Antonella Adinolfi, Fabio Becce, Hilde Berner Hammer, Tomas Cazenave, Edoardo Cipolletta, Sara Nysom Christiansen, Andrea Delle Sedie, Mario Diaz, Fabiana Figus, Peter Mandl, Daryl MacCarter, Mohamed A Mortada, Gael Mouterde, Francesco Porta, Anthony M Reginato, Wolfgang A Schmidt, Teodora Serban, Richard J Wakefield, Pascal Zufferey, Piercarlo Sarzi-Puttini, Anna Zanetti, Arianna Damiani, Carlos Pineda, Helen I Keen, Maria Antonietta D'Agostino, Georgios Filippou
Journal: The Lancet Rheumatology (2023)
Effects of putative metformin targets on phenotypic age and leukocyte telomere length: a mendelian randomisation study using data from the UK Biobank
Authors: Shan Luo, Ian Chi Kei Wong, Celine Sze Ling Chui, Jie Zheng, Yuan Huang, Catherine Mary Schooling, Shiu Lun Au Yeung
Journal: The Lancet Healthy Longevity (2023)

Metformin, a first-line medication for type 2 diabetes, might also have a protective effect against ageing-related diseases, but so far little experimental evidence is available. We sought to assess the target-specific effect of metformin on biomarkers of ageing in the UK Biobank.
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
Authors: Gerhard Held, Lorenz Thurner, Viola Poeschel, German Ott, Christian Schmidt, Konstantinos Christofyllakis, Andreas Viardot, Peter Borchmann, Walburga Engel-Riedel, Norbert Frickhofen, Maike Nickelsen, Ofer Shpilberg, Mathias Witzens-Harig, Frank Griesinger, Beate Krammer-Steiner, Andreas Neubauer, Peter de Nully Brown, Massimo Federico, Bertram Glass, Norbert Schmitz, Gerald Wulf, Lorenz Truemper, Moritz Bewarder, Niels Murawski, Stephan Stilgenbauer, Andreas Rosenwald, Bettina Altmann, Marianne Engelhard, Heinz Schmidberger, Jochen Fleckenstein, Christian Berdel, Markus Loeffler, Marita Ziepert
Journal: HemaSphere (2023)

UNFOLDER (NCT00278408, EUDRACT 2005-005218-19) is a phase-3 trial in patients with aggressive B-cell lymphoma and intermediate prognosis, including primary mediastinal B-cell lymphoma (PMBCL). In a 2 × 2 factorial design, patients were randomized to 6× R-CHOP-14 or R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prediso(lo)ne) and to consolidation radiotherapy to extralymphatic/bulky disease or observation. Response was assessed according to the standardized criteria from 1999, which did not include F-18 fluordesoxyglucose positron emission tomography/computed tomography (FDG-PET) scans. Primary end point was event-free survival (EFS). A subgroup of 131 patients with PMBCLs was included (median age, 34 y; 54% female, 79% elevated lactate dehydrogenase (LDH), 20% LDH >2× upper limit of normal [ULN], and 24% extralymphatic involvement). Eighty-two (R-CHOP-21: 43 and R-CHOP-14: 39) patients were assigned to radiotherapy and 49 (R-CHOP-21: 27, R-CHOP-14: 22) to observation. The 3-year EFS was superior in radiotherapy arm (94% [95% confidence interval (CI), 89-99] versus 78% [95% CI, 66-89]; P = 0.0069), due to a lower rate of partial responses (PRs) (2% versus 10%). PR triggered additional treatment, mostly radiotherapy (n = 5; PR: 4; complete response/unconfirmed complete response: 1). No significant differences were observed in progression-free survival (PFS) (95% [95% CI, 90-100] versus 90% [95% CI, 81-98]; P = 0.25) nor in overall survival (OS) (98% [95% CI, 94-100] versus 96% [95% CI, 90-100]; P = 0.64). Comparing R-CHOP-14 and R-CHOP-21, EFS, PFS, and OS were not different. A prognostic marker for adverse outcome was elevated LDH >2× ULN (EFS: P = 0.016; PFS: P = 0.0049; OS: P = 0.0014). With the limitation of a pre-PET-era trial, the results suggest a benefit of radiotherapy only for patients responding to R-CHOP with PR. PMBCL treated with R-CHOP have a favorable prognosis with a 3-year OS of 97%.
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
Authors: Lorenz Thurner, Marita Ziepert, Christian Berdel, Christian Schmidt, Peter Borchmann, Dominic Kaddu-Mulindwa, Andreas Viardot, Mathias Witzens-Harig, Judith Dierlamm, Mathias Haenel, Bernd Metzner, Gerald Wulf, Eva Lengfelder, Ulrich B. Keller, Norbert Frickhofen, Maike Nickelsen, Tobias Gaska, Frank Griesinger, Rolf Mahlberg, Reinhard Marks, Ofer Shpilberg, Hans-Walter Lindemann, Martin Soekler, Ludwig Fischer von Weikersthal, Michael Kiehl, Eva Roemer, Martin Bentz, Beate Krammer-Steiner, Ralf Trappe, Peter de Nully Brown, Massimo Federico, Francesco Merli, Marianne Engelhard, Bertram Glass, Norbert Schmitz, Lorenz Truemper, Moritz Bewarder, Frank Hartmann, Niels Murawski, Stephan Stilgenbauer, Andreas Rosenwald, Bettina Altmann, Heinz Schmidberger, Jochen Fleckenstein, Markus Loeffler, Viola Poeschel, Gerhard Held
Journal: HemaSphere (2023)

UNFOLDER (Unfavorable Young Low-Risk Densification of R-Chemo Regimens) is an international phase-3 trial in patients 18–60 years with aggressive B-cell lymphoma and intermediate prognosis defined by age-adjusted International Prognostic Index (aaIPI) of 0 and bulky disease (≥7.5 cm) or aaIPI of 1. In a 2 × 2 factorial design patients were randomized to 6× R-CHOP-14 or 6× R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prediso[lo]ne) and to consolidation radiotherapy to extralymphatic and bulky disease or observation. Response was assessed according to the standardized response criteria published in 1999, not including F-18 fluordesoxyglucose positron emission tomography/computed tomography (FDG-PET). Primary endpoint was event-free survival (EFS). A total of 695 of 700 patients were eligible for the intention-to-treat analysis. Totally 467 patients qualified for radiotherapy of whom 305 patients were randomized to receive radiotherapy (R-CHOP-21: 155; R-CHOP-14: 150) and 162 to observation (R-CHOP-21: 81, R-CHOP-14: 81). Two hundred twenty-eight patients not qualifying for radiotherapy were randomized for R-CHOP-14 versus R-CHOP-21. After a median observation of 66 months 3-year EFS was superior in the radiotherapy-arm versus observation-arm (84% versus 68%; P = 0.0012), due to a lower rate of partial responses (PR) (2% versus 11%). PR often triggered additional treatment, mostly radiotherapy. No significant difference was observed in progression-free survival (PFS) (89% versus 81%; P = 0.22) and overall survival (OS) (93% versus 93%; P = 0.51). Comparing R-CHOP-14 and R-CHOP-21 EFS, PFS and OS were not different. Patients randomized to radiotherapy had a superior EFS, largely due to a lower PR rate requiring less additional treatment (NCT00278408, EUDRACT 2005-005218-19).